ABBV vs REGN
By Alex · Tickerpine
AbbVie Inc. vs Regeneron Pharmaceuticals, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | REGN |
|---|---|---|
| Price | $253.35 | $632.90 |
| Market cap | $447.62B | $66.35B |
| P/E ratio | 123.6 | 15.5 |
| ROE | — | 14.55% |
| Profit margin | 5.79% | 29.65% |
| Revenue growth | 12.40% | 19.00% |
| Dividend yield | 2.73% | 0.59% |
| Beta | 0.31 | 0.24 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs REGN in plain English
- ABBV is the bigger company — about 6.7× the market cap of REGN.
- REGN is cheaper on earnings (P/E 15.5 vs 123.6).
- REGN is growing revenue faster (19% vs 12%).
- ABBV has the higher dividend yield (2.73% vs 0.59%).
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
REGN return calculator
See what $1,000 in Regeneron Pharmaceuticals, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.